EDAP TMS SA - 10-Q Filing Summary (Q1 2026)
Business Context and Reporting Period
This is the first quarterly report filed by EDAP TMS SA as a U.S. domestic issuer, covering the period ended March 31, 2026. The company develops and distributes non-invasive medical devices, primarily for urological diseases, organized into three segments: High Intensity Focused Ultrasound (HIFU), Lithotripsy (ESWL), and Distribution. Management has shifted strategy to prioritize HIFU growth while de-emphasizing ESWL and Distribution activities.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $17.8 million | $14.3 million |
| Gross Profit | $8.1 million | $6.0 million |
| Gross Margin | 45.7% | 42.0% |
| Operating Loss | $(7.4) million | $(6.3) million |
| Net Loss | $(9.1) million | $(7.4) million |
| Diluted EPS | $(0.24) | $(0.20) |
| Cash and Equivalents (End of Period) | $15.0 million | $24.7 million |
| Operating Cash Flow | $(3.0) million | $(5.3) million |
| Total Debt (Current + Non-Current) | $19.1 million | $18.0 million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 24.8% year-over-year, driven primarily by the HIFU division which grew 78.3% to $11.6 million. This was fueled by a 146.7% increase in medical device sales (11 Focal One units sold vs. 6 in Q1 2025).
- Segment Performance: While HIFU surged, the ESWL division revenue declined 15.8% and the Distribution division declined 21.2%, consistent with the strategic pivot away from legacy businesses.
- Expense Increases: Operating expenses rose 26% to $15.5 million. General and administrative expenses jumped 58.5% largely due to fees associated with transitioning to U.S. domestic filer status.
- Financial Expenses: Net financial expense was $1.7 million, a significant increase from $15k income in the prior year. This was driven by a $1.3 million loss on the fair value adjustment of warrants issued to the European Investment Bank (EIB).
- Liquidity: Cash reserves decreased by $5.4 million during the quarter. However, the company drew Tranche B of its EIB credit facility (€12 million) in April 2026 (subsequent event).
Outlook, Risks, and Management Commentary
- Going Concern: Management states that while the recent EIB drawdown provides sufficient funds for at least 12 months, the company has a history of losses and may need to raise substantial additional financing to achieve profitability. There is uncertainty regarding the ability to raise capital on acceptable terms.
- Strategic Focus: The company continues to focus on commercializing the Focal One robotic HIFU system, particularly in the U.S. market, while reducing emphasis on ESWL and Distribution.
- Risks: Key risks include the ability to raise capital, regulatory approval uncertainties for HIFU devices, reimbursement status, intense competition, and foreign exchange fluctuations (Euro vs. USD/JPY).
- Subsequent Events: On April 20, 2026, the company received €12 million from the EIB under Tranche B of its credit facility.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the €12 million EIB Tranche B proceeds against the current burn rate and the timeline to profitability.
- HIFU Adoption: Confirm the sustainability of the 146.7% growth in Focal One unit sales and the conversion rate of leases/RPPs to capital sales.
- Warrant Liability: Monitor the fair value volatility of the EIB warrants, which significantly impacted Q1 net loss and could continue to affect earnings.
- Regulatory Status: Track the clinical and regulatory progress of HIFU devices in key markets, particularly the U.S., as this is central to the growth strategy.
- Cost Structure: Assess whether the 58.5% increase in G&A expenses is a one-time transition cost or a new baseline for operating expenses.